Becton, Dickinson and Company (BD) has reported revenues of $5bn for the first quarter of the year, which ended on 31 March.

The figure represents a 2.1% increase compared to the $4.9bn recorded in the prior-year quarter.

Related Company Profiles

View all

The growth was driven by an 8.2% increase in base revenues on a reported basis. However, BD’s Covid-only testing revenues fell to $214m in the quarter, from $474m reported in the same period a year ago.

Net income in the first three-month period of 2022 totalled $454m, up 51.7% compared to $299m in the first quarter of 2021.

Quarterly net income applicable to common shareholders also grew year-over-year (Y-o-Y), from $277m to $431m.

See Also:

The company’s BD Medical and BD Interventional business segments recorded 4.5% and 9.9% growth in revenues, respectively, in Q1 2022.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Meanwhile, quarterly revenues of the BD Life Sciences unit fell 6.4%, to $1.4bn, on a Y-o-Y basis.

BD chairman, CEO and president Tom Polen said: “We delivered another quarter of strong growth across our base business through continued focused execution and progress against our BD2025 strategy, despite a dynamic and challenging macro environment.

“Our Grow-Simplify-Empower initiatives, innovation pipeline and capital deployment strategy are demonstrating momentum and we remain well-positioned to drive long-term growth and value for shareholders.”

During the quarter, BD completed the acquisition of Cytognos. The deal expands BD’s portfolio of blood cancer diagnostics, immune assessment tests and informatics.

It also introduced the new BD Rhapsody TCR/BCR Multiomic Assay.

Last month, the company launched a new family of BD reagents to support the development of drugs for different diseases.